Working… Menu

A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04752566
Recruitment Status : Not yet recruiting
First Posted : February 12, 2021
Last Update Posted : March 5, 2021
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:

This is a Phase 3, prospective, multicenter, placebo controlled, double blind, randomized study to investigate the efficacy and safety of eculizumab in participants with severe GBS, defined using the Hughes Functional Grade (FG) scale as progressively deteriorating FG3 or FG4/FG5 within 2 weeks from onset of weakness due to GBS.

This study will be conducted only at sites in Japan.

Condition or disease Intervention/treatment Phase
Guillain-Barre Syndrome Biological: Eculizumab Drug: Placebo Phase 3

Detailed Description:
Eligible participants will be randomized to receive intravenous (IV) infusion of eculizumab or placebo at a 2:1 ratio. All participants will be on concomitant IV immunoglobulin G (Ig) therapy as per standard of care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS)
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Eculizumab

Arm Intervention/treatment
Experimental: Eculizumab
Participants will receive eculizumab.
Biological: Eculizumab
Eculizumab will be administered via IV infusion once a week for 4 weeks.
Other Name: Soliris

Placebo Comparator: Placebo
Participants will receive placebo.
Drug: Placebo
Placebo will be administered via IV infusion once a week for 4 weeks.

Primary Outcome Measures :
  1. Time To First Reaching A Hughes FG Score ≤ 1 [ Time Frame: Up to Week 24 ]

Secondary Outcome Measures :
  1. Proportion Of Participants With A Hughes FG Score ≤ 1 [ Time Frame: Week 24 ]
  2. Proportion Of Participants With A Hughes FG Score Improvement Of ≥ 3 [ Time Frame: Week 24 ]
  3. Proportion Of Participants With A Hughes FG Score ≤ 1 [ Time Frame: Week 8 ]
  4. Incidence Of Treatment-emergent Adverse Events [ Time Frame: Up to Week 24 ]
  5. Free Complement Component 5 In Serum [ Time Frame: Week 24 ]
  6. Hemolytic Complement Activity In Serum [ Time Frame: Week 24 ]
  7. Length Of Stay In The Hospital [ Time Frame: Up to Week 24 ]
  8. Duration Of Ventilator Support [ Time Frame: Up to Week 24 ]
  9. Concentration Of Eculizumab In Serum [ Time Frame: Up to Week 24 ]
  10. Incidence Of Antidrug Antibodies [ Time Frame: Up to Week 24 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants who meet the GBS criteria.
  • Participants who were able to run prior to onset of GBS symptoms.
  • Participants with onset of weakness due to GBS < 2 weeks before screening.
  • Participants unable to walk unaided for ≥ 5 meters (progressively deteriorating FG3 or FG4 to FG5).
  • Participants who are already on IVIg or deemed eligible for and who will start IVIg.
  • Participants who can start their first dose of study drug before the end of the IVIg treatment period.

Exclusion Criteria:

  • Participants who have previously received or are currently receiving treatment with complement modulators.
  • Participants who have been administered another investigational product within 30 days or 5 half-lives (whichever is longer) prior to providing consent or are currently participating in another interventional study.
  • Participants who have received rituximab within 12 weeks prior to screening.
  • Participants who are being considered for or are already on plasmapheresis.
  • Participants who have received immunosuppressive treatment during the 4 weeks prior to providing consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04752566

Layout table for location contacts
Contact: Alexion Pharmaceuticals Inc. 855-752-2356

Sponsors and Collaborators
Alexion Pharmaceuticals
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals Identifier: NCT04752566    
Other Study ID Numbers: ECU-GBS-301
First Posted: February 12, 2021    Key Record Dates
Last Update Posted: March 5, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alexion Pharmaceuticals:
C5 Inhibition Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Guillain-Barre Syndrome
Pathologic Processes
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Autoimmune Diseases
Immune System Diseases